Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5918331 | Molecular Immunology | 2008 | 11 Pages |
Abstract
The complement system is important for protection from invading pathogens, removal of waste products and guidance of the immune response. Furthermore, complement can be also targeted to cancer cells. However, membrane-bound inhibitors over-expressed by certain types of tumor cells restrict the cytotoxic activity of complement. Herein we report that non-small cell lung cancer (NSCLC) cells produce soluble complement inhibitors factor I (FI) and C4b-binding protein (C4BP). FI is a serine protease capable of degrading the activated complement components C3b and C4b, whilst C4BP acts as its cofactor. Furthermore, NSCLC cells express membrane-bound regulators and shed membrane cofactor protein (MCP), which shares cofactor function with C4BP. Secretion of FI from NSCLC cells was higher than previously reported for any non-hepatic source and FI produced by these cells could efficiently support cleavage of C3b and C4b. In vitro functional assays revealed that additional FI significantly decreased C3 deposition and complement-dependent lysis, particularly when cofactors were added. Our results demonstrate that soluble inhibitors produced by NSCLC cells may provide further protection from complement beyond the level ensured by membrane-bound inhibitors and, as such, contribute to the aggressive phenotype of these lung cancer cells.
Keywords
ADCCMCPCDCmembrane cofactor protein (CD46)DAFFHL-1PKCC4bpCCPCDCCTumorComplement factor HImmune systemNSCLCNon-small cell lung cancerCytotoxicityAntibody-dependent cell cytotoxicitycomplement-dependent cytotoxicityComplement Factor IComplementMACC4b-binding proteinProtein Scomplement control proteinProtein kinase Ccomplement receptor 1
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Biology
Authors
Marcin Okroj, Yi-Fan Hsu, Daniel Ajona, Ruben Pio, Anna M. Blom,